幼年皮肌炎达标治疗策略:合适的目标及达成时机
该研究为回顾性研究,纳入两个三级中心的187例幼年皮肌炎患者,旨在确定治疗反应时间以支持达标治疗策略制定。患者平均在治疗后3个月实现肌酶正常化、6个月实现肌肉缓解、12个月内实现皮肤缓解;达到非活动性疾病的中位时间在Gaslini为10.3个月、SickKids为8.8个月。
要点
- 肌酶正常化平均在治疗开始后3个月,肌肉缓解平均在6个月。
- 皮肤缓解在治疗开始后12个月内出现。
- 达到非活动性疾病的中位时间Gaslini为10.3个月,SickKids为8.8个月。
核心结论
- 该研究为JDM达标治疗策略提供了真实世界数据,提示潜在的目标时间线。
研究设计与样本
- 回顾性研究,纳入两个三级中心(IRCCS Istituto Giannina Gaslini和The Hospital for Sick Children) physician-confirmed诊断的JDM患者187例,平均诊断年龄8岁,收集诊断后前两年的 demographic和临床数据,采用Kaplan-Meier生存曲线确定至结局定义的时间。
主要发现
- 患者平均在治疗开始后3个月实现肌酶正常化,6个月实现肌肉缓解。
- 皮肤缓解在治疗开始后12个月内出现。
- 达到非活动性疾病的中位时间Gaslini为10.3个月,SickKids为8.8个月,两中心间存在差异。
临床怎么用
- 该研究提供的真实世界时间线可支持JDM达标治疗策略中目标及达成时机的制定。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Juvenile dermatomyositis (JDM) is a rare autoimmune condition. The treat-to-target strategy has garnered interest in pediatric rheumatology. It is based on defining clear therapeutic targets, with frequent disease activity monitoring, and adjustment of the treatments if targets are not met within a defined time frame. Recently, an international task force of experts launched an initiative aimed at the development of recommendations for the adoption of treat-to-target strategy in JDM. This study was done to support those recommendations. We aimed to determine the time-to-treatment response in patients with JDM, to better inform the development of a treat-to-target strategy in JDM. METHODS: This is a retrospective review of patients with a physician-confirmed diagnosis of JDM, observed at two tertiary care centers-the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Giannina Gaslini (Gaslini), and The Hospital for Sick Children (SickKids). Demographic and clinical data were obtained on all patients with JDM during the first two years following diagnosis. Kaplan-Meier survival curves were used to determine time to outcome definitions. RESULTS: A total of 187 patients were identified across two sites; the mean age of diagnosis was 8 years. On average, patients with JDM achieved normalization of muscle enzymes and muscle remission three months and six months after treatment initiation, respectively. Skin remission occurred within 12 months after starting treatment. Time to reach inactive disease varied between the sites, with median time being 10.3 months (Gaslini) and 8.8 months (SickKids). CONCLUSION: This study provides real-world data for potential timelines to target with a treat-to-target strategy for JDM.
引用
- MacMahon JM, Ravelli A, Rebollo-Giménez AI, et al. Toward a Treat-to-Target Strategy in Juvenile Dermatomyositis: What Are the Suitable Targets and Optimal Timing of Their Achievement? Arthritis Rheumatol. 2026. PMID: 41211633. doi:10.1002/art.43431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。